Proceedings of International Scientific and Practical Conference “Russia 2020 - a new reality: economy and society” (ISPCR 2020)

Preferential Provision of Medicines – Economic Problems and the Need for Reforming

Authors
T.I. Okonenko, M.S. Tokmachov, G.A. Antropova, E.S. Egorova, A.K. Khrutsky
Corresponding Author
T.I. Okonenko
Available Online 24 February 2021.
DOI
10.2991/aebmr.k.210222.048How to use a DOI?
Keywords
regional budget, financing of pharmaceutical provision, price, preferential drug provision
Abstract

The aging of the population in the Russian Federation and other countries has led to an increase in the number of chronic non-communicable diseases requiring higher costs of medical care. A 10% increase in the proportion of the aging population with chronic diseases reduces economic growth by 0.5% per year. Therapy with genetically engineered biological preparations for chronic diseases of the musculoskeletal system is burdensome for regional budgets, because patients suffering from these diseases receive drugs under the subsidized drug provision. The article discusses the need to reform the system of preferential provision on the example of RA patients receiving genetically engineered biological drugs (GEBD). Among all RA patients who chose preferential drug provision, the proportion of patients receiving GIBP grew from 1.88% in 2011 to 6.20% in 2017 with a further tendency to decline, which is probably due to the fact that in the period 2018-2019 in the Novgorod region, there was a change in the procedure for receiving GIBP by patients with RA. Since 2019, their purchase has been made only by the regional clinical hospital as part of the provision of high-tech medical care, and patients with RA receive them parenterally in the rheumatology department, where they are hospitalized for 1-2 days. Therefore, most likely, such a reorganization of the system is associated with a decrease in drug procurement in 2018. In addition, such a system for providing patients with preferential drugs is also designed to eliminate interruptions in the provision of “preferential” prescriptions with necessary drugs.

Copyright
© 2021, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

Volume Title
Proceedings of International Scientific and Practical Conference “Russia 2020 - a new reality: economy and society” (ISPCR 2020)
Series
Advances in Economics, Business and Management Research
Publication Date
24 February 2021
ISBN
978-94-6239-341-7
ISSN
2352-5428
DOI
10.2991/aebmr.k.210222.048How to use a DOI?
Copyright
© 2021, the Authors. Published by Atlantis Press.
Open Access
This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - CONF
AU  - T.I. Okonenko
AU  - M.S. Tokmachov
AU  - G.A. Antropova
AU  - E.S. Egorova
AU  - A.K. Khrutsky
PY  - 2021
DA  - 2021/02/24
TI  - Preferential Provision of Medicines – Economic Problems and the Need for Reforming
BT  - Proceedings of International Scientific and Practical Conference “Russia 2020 - a new reality: economy and society” (ISPCR 2020)
PB  - Atlantis Press
SP  - 245
EP  - 249
SN  - 2352-5428
UR  - https://doi.org/10.2991/aebmr.k.210222.048
DO  - 10.2991/aebmr.k.210222.048
ID  - Okonenko2021
ER  -